Ionis Pharmaceuticals, Inc. (IONS) key performance indicators and operating metrics (14 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Net product sales | 43M | FY2026-Q1 |
| SPINRAZA (nusinersen) royalty revenue | 44M | FY2026-Q1 |
| WAINUA (eplontersen) royalty revenue | 11M | FY2026-Q1 |
| Total commercial revenue | 108M | FY2026-Q1 |
| Total research and development revenue | 138M | FY2026-Q1 |
| Income (loss) from operations (non-GAAP) | 75M | FY2026-Q1 |
| Operating expenses (non-GAAP) | 321M | FY2026-Q1 |
| Research and development milestone payments (clinical and regulatory) | 95M | FY2026-Q1 |
| Collaboration agreement revenue | 52M | FY2025-Q4 |
| Other commercial revenue | 8M | FY2025-Q4 |
| Other royalties | 6M | FY2025-Q4 |
| Royalty revenue | 76M | FY2025-Q4 |
| Tringolza net product sales | 50M | FY2025-Q4 |
| WAINUA joint development revenue | 10M | FY2025-Q4 |
Back to IONS overview · IONS earnings · IONS holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.